Value through Innovation17 April 2014

55 years in Brazil - Successful brands and potential for more

In January 2011, when Boehringer Ingelheim was celebrating its 125th year worldwide, the Brazilian subsidiary had a further reason to celebrate: it has operated in this country for 55 years. The robust portfolio, consisting of 30 prescription medicines, medicines for hospital use and 16 over-the-counter (OTC) products, would have been good enough reason for the company to be proud, but the year was only beginning for Boehringer Ingelheim in Brazil. An even more promising future started to emerge a few months later with the approval of Pradaxa® and then Trayenta®. Both secured approval very early due to the innovation- friendly environment created by the regulatory authorities and the professionalism of the Brazilian subsidiary.

In 2011, Brazilian employees had yet another good reason to be proud of being part of this team: the company was placed 14th in the 100 Best Places to Work ranking, organised by the Great Place to Work Institute. One of the factors that contributed for this placing in the survey was the philosophy implemented in 2010 to improve the environmental sustainability of the office, and thereby the quality of life and well-being of the employees.

Company employees moved to an environmentally friendly building with progressive and innovative architectural design that meets strict sustainability criteria, and is laid out so as to foster integration and stimulate creativity. Among the strong Boehringer Ingelheim brands in the country, products that stand out are the analgesic Anador®, which in 2012, has been available for 55 years as one of the leading medications in this sector in Brazil, and Buscopan® Composto, the 9th best-selling medicine in the country. In 2011, Buscopan ® Composto and Anador® respectively accounted for 11.1 % and 11.9 % of turnover. Sales of these and other OTC medicines accounted for 48 % of Boehringer Ingelheim business in the country.

In animal health, sales of vaccines for prevention of swine diseases have also increased in Brazil. Sales of Vetmedica Brasil increased by 17.4 % in 2011 compared to 2010, amounting to BRL 47.6 million.

The main growth driver was Ingelvac CircoFLEX®, with sales growth of around 13.7 %. Other marketed products in this sector include Ingelvac MycoFLEX®, Ingelvac® DART, Ingelvac® HP1 and Enterisol® Ileitis.

The Brazilian plant manufactured 84.5 million packs in 2011 for supplying local, regional and international markets and was recognised by Sindusfarma (Syndicate of Pharmaceutical Product Industries in the State of São Paulo) as one of the three best pharmaceutical service providers in Brazil.

Through the process of switching to lean manufacturing, that began in 2010, the plant should become one the most competitive plants in the Established Products network. The plant complex occupies an area of 29,000 m2 on a 210.000 m2 site. 350 employees work there and it manufactures top-selling products, such as Anador® and Buscopan® and others, Medicines, such as Dexa® Rhino Spray and Buscapina® are shipped to Europe and North, South and Middle America. In addition, another 110 items are exported. A total of 84 million packs were produced.

Meeting social-environmental criteria is another difference with a powerful presence at the manufacturing plant.
The plant invests in preserving the environment and has taken measures that have led to a reduction of pollutant emissions. It also contributes to the considerate care of natural resources, the control and treatment or incineration of solid and liquid waste as well as the extension of recycling activities through collection, separation and reuse of materials, such as paper, plastic, glass, metals and printer cartridges and ink.

In the past years, the plant has invested over USD 75 million both in technological modernisation of its processes and facilities as well as in ensuring staff is qualified to meet strict international standards and thereby increase exports The plant has Good Manufacturing Practices certification that allows medicine production for export to Mercosur, Pacto Andino and Europe.